Drug discovery in the next millennium

被引：79

作者：

Ohlstein, EH ^{[1
]}

Ruffolo, RR

Elliott, JD

机构：

[1] SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, Res & Dev, King Of Prussia, PA 19406 USA

[2] SmithKline Beecham Pharmaceut, Dept Med Chem, Res & Dev, King Of Prussia, PA 19406 USA

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2000年 / 40卷

关键词：

target validation; functional genomics; proteomics; high-throughput screening; combinatorial chemistry; cheminformatics; gene therapy;

D O I：

10.1146/annurev.pharmtox.40.1.177

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Selection and validation of novel molecular targets have become of paramount importance in light of the plethora of new potential therapeutic drug targets that have emerged from human gene sequencing. In response to this revolution within the pharmaceutical industry, the development of high-throughput methods in both biology and chemistry has been necessitated. This review addresses these technological advances as well as several new areas that have been created by necessity to deal with this new paradigm, such as bioinformatics, cheminformatics, and functional genomics. With many of these key components of future drug discovery now in place, it is possible to map out a critical path for this process that will be used into the new millennium.

引用

收藏

页码：177 / 191

页数：15

相关论文

共 39 条

[11] Discovery of potent nonpeptide vitronectin receptor (alpha(v)beta(3)) antagonists [J].

Keenan, RM ;

Miller, WH ;

Kwon, C ;

Ali, FE ;

Callahan, JF ;

Calvo, RR ;

Hwang, SM ;

Kopple, KD ;

Peishoff, CE ;

Samanen, JM ;

Wong, AS ;

Yuan, CK ;

Huffman, WF .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (15) :2289-2292

[12] Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene [J].

Kozarsky, KF ;

Jooss, K ;

Donahee, M ;

Strauss, JF ;

Wilson, JM .

NATURE GENETICS, 1996, 13 (01) :54-62

[13] The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene [J].

Lin, L ;

Faraco, J ;

Li, R ;

Kadotani, H ;

Rogers, W ;

Lin, XY ;

Qiu, XH ;

de Jong, PJ ;

Nishino, S ;

Mignot, E .

CELL, 1999, 98 (03) :365-376

[14] Diffusion-edited NMR-affinity NMR for direct observation of molecular interactions [J].

Lin, MF ;

Shapiro, MJ ;

Wareing, JR .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (22) :5249-5250

[15] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].

Lipinski, CA ;

Lombardo, F ;

Dominy, BW ;

Feeney, PJ .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25

[16] High density synthetic oligonucleotide arrays [J].

Lipshutz, RJ ;

Fodor, SPA ;

Gingeras, TR ;

Lockhart, DJ .

NATURE GENETICS, 1999, 21 (Suppl 1) :20-24

[17] Gene therapy for myocardial angiogenesis -: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia [J].

Losordo, DW ;

Vale, PR ;

Symes, JF ;

Dunnington, CH ;

Esakof, DD ;

Maysky, M ;

Ashare, AB ;

Lathi, K ;

Isner, JM .

CIRCULATION, 1998, 98 (25) :2800-2804

[18] Structure of bacteriorhodopsin at 1.55 Å resolution [J].

Luecke, H ;

Schobert, B ;

Richter, HT ;

Cartailler, JP ;

Lanyi, JK .

JOURNAL OF MOLECULAR BIOLOGY, 1999, 291 (04) :899-911

[19]

*NIH, NAT HUM GEN RES I

[20] SB-209670, A RATIONALLY DESIGNED POTENT NONPEPTIDE ENDOTHELIN RECEPTOR ANTAGONIST [J].

OHLSTEIN, EH ;

NAMBI, P ;

DOUGLAS, SA ;

EDWARDS, RM ;

GELLAI, M ;

LAGO, A ;

LEBER, JD ;

COUSINS, RD ;

GAO, AM ;

FRAZEE, JS ;

PEISHOFF, CE ;

BEAN, JW ;

EGGLESTON, DS ;

ELSHOURBAGY, NA ;

KUMAR, C ;

LEE, JA ;

YUE, TL ;

LOUDEN, C ;

BROOKS, DP ;

WEINSTOCK, J ;

FEUERSTEIN, G ;

POSTE, G ;

RUFFOLO, RR ;

GLEASON, JG ;

ELLIOTT, JD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8052-8056

← 1 2 3 4 →